Arab Pharmaceuticals Reports EGP 238.3 Million Net Profit in the First 11 Months, Up 14%; Targets EGP 1.652 Billion in Sales for FY 2026/2027

The financial results of Arab Pharmaceuticals and Chemical Industries Company for the period from July 2025 to the end of May 2026 demonstrated strong business performance, with net profit after tax rising to EGP 238.333 million, compared to EGP 209.205 million during the same period of the previous fiscal year, representing a 14% year-on-year increase.

The company also reported a significant increase in net sales, which grew by 23% to EGP 1.265 billion, compared to EGP 1.031 billion in the corresponding period of the previous fiscal year. This reflects continued improvement in the company's operating performance and sales growth.

In a related development, the Board of Directors of Arab Pharmaceuticals and Chemical Industries Company approved the budget plan for fiscal year 2026/2027, aiming to maintain its positive growth momentum.

The company targets sales of EGP 1.652 billion for FY 2026/2027, compared to EGP 1.380 billion in the previous year's budget. It also aims to achieve net profit of EGP 291 million, up from EGP 273 million projected in the previous fiscal year's budget.

Dr. Nevine Raafat Abdallah, Chief Executive Officer of Arab Pharmaceuticals and Chemical Industries Company, stated that the company's financial performance and the newly approved budget reflect its commitment to sustaining growth, strengthening operational efficiency, and delivering improved financial results in the coming fiscal year.